Statement re FDA announcement

RNS Number : 5496H
Imperial Brands PLC
16 November 2018
 

16 November 2018

 

Imperial Brands responds to FDA announcement

 

We welcome the US Food and Drug Administration's (FDA) moves to prevent youth access to tobacco and vapour products.  We share the same concerns and objectives as the FDA: the use by minors of these products is completely unacceptable. Vapour products are for adult smokers and their sale to anyone underage should be prevented. However, we also recognise the challenge faced by the FDA in balancing concerns regarding youth appeal and access, given the positive public health potential of vapour products.

 

We believe that through our blu product range we offer adult smokers a significantly better alternative than combustible cigarettes and consistently reinforce this message, while at the same time working actively against youth access to, and usage of, our products.

 

On the FDA's specific actions, we welcome its commitment to standards for effective age verification for all online sales of vapour products; a technology which we already use on blu.com.

 

We recognise the FDA's concern over age verification at brick-and-mortar retail outlets and will consider further appropriate actions. The availability of quality vaping products like blu in outlets where tobacco products are sold is vital to help adults transition away from combustible tobacco.

 

We are developing a connected version of myblu with device locking technology and are greatly encouraged by Commissioner Gottlieb's comment on a process to accelerate development and review of vapour products with child protection features.

 

We also note today the FDA's proposals regarding menthol cigarettes and flavoured cigars, which would need to be supported by the relevant science and other evidence. Such proposals are likely to require a multi-year process, in which we will be fully engaged.

 

ENDS

 

 

Investor Contacts

Media Contacts

Peter Durman

+44 (0)7970 328 903

Alex Parsons

+44 (0)7967 467 241

Matt Sharff

+44 (0)7964 110 921

Simon Evans

+44 (0)7967 467 684

Mat Slade

+44 (0)7811 974 438



 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRGGGQPGUPRGBA
UK 100

Latest directors dealings